Clinical Evaluation of T Component in the Ninth Edition TNM Classification of Thymic Epithelial Tumors [0.03%]
第九版世界卫生组织胸腺上皮性肿瘤T分期的临床评估
Yulong Wang,Wenhan Weng,Xin Wang et al.
Yulong Wang et al.
Objectives: The optimal staging system for thymic epithelial tumors (TETs) remains controversial. This study aimed to evaluate the clinical utility of the T component in the latest ninth edition of the TNM staging system....
Neoadjuvant Chemoimmunotherapy Combined With Node-Sparing Radiotherapy for Clinical T3N+ Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Single-Arm, Phase II Study (CINSREC Trial) [0.03%]
新辅助化疗免疫治疗结合保淋巴结同期放疗治疗临床T3N+局部晚期食管鳞癌前瞻性单组二期研究(CINSREC试验)
Xu Zhou,Chunji Chen,Ya Zeng et al.
Xu Zhou et al.
Introduction: The promising therapeutic outcomes of neoadjuvant chemoimmunotherapy (NCIT) in locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by multiple phase II clinical trials and are wide...
Clinical Trial
Thoracic cancer. 2025 Nov;16(22):e70191. DOI:10.1111/1759-7714.70191 2025
Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer [0.03%]
表皮生长因子受体突变非小细胞肺癌患者一线使用奥希替尼进展后影响二线治疗选择的初始因素分析
Hiroaki Kodama,Haruyasu Murakami,Nobuaki Mamesaya et al.
Hiroaki Kodama et al.
Background: Osimertinib, an irreversible third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), improves survival in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However,...
Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real-World Pharmacovigilance Analysis Using FAERS Data [0.03%]
基于FAERS数据的免疫检查点抑制剂相关肝胆不良事件的药物警戒分析
Yuzhu Chen,Yixin Zeng,Kaisheng Zhang et al.
Yuzhu Chen et al.
Background: Immune checkpoint inhibitors (ICIs) improve cancer outcomes but cause significant hepatobiliary toxicity (e.g., liver dysfunction, immune-mediated liver disease). Prior studies were limited to small samples or...
Burden of Breast Cancer and Its Attributable Risk Factors in the Belt and Road Initiative Countries, 1990-2021 [0.03%]
“一带一路”国家乳腺癌疾病负担及可归因风险因素（1990—2021年）
Tiankun Wang,Huimin He,Hao Zi et al.
Tiankun Wang et al.
Background: This study evaluated the burden of breast cancer (BC) in Belt and Road Initiative (BRI) countries from 1990 to 2021 by age, sex, and risk factors, aiming to guide health promotion. ...
Tolerability of Surgery by Patients With Third Primary Lung Cancer After Second Primary Lung Cancer Surgery [0.03%]
第三次原发性肺癌患者接受手术的耐受性研究:第二次原发性肺癌术后患者的 tolerability 分析
Hideomi Ichinokawa,Kazuya Takamochi,Yukio Watanabe et al.
Hideomi Ichinokawa et al.
Purpose: This study aimed to clarify the incidences and treatments of enlarged nodules detected using imaging findings during follow-up, surgical outcomes, and prognosis for patients who underwent a second surgery for pri...
Effect of Particulate Matter Pollution on Global Lung Cancer Burden: A Systematic Analysis for the Global Burden of Disease Study 1990-2021 [0.03%]
全球大气颗粒物污染对肺癌疾病负担的影响：1990年至2021年全球疾病负担研究的系统分析
Yuhao Chen,Xinyue Yang,Hongbin Zhang et al.
Yuhao Chen et al.
Background: Lung cancer remains a leading cause of cancer mortality globally, with particulate matter pollution (PMP) identified as a critical environmental risk. This study analyzes long-term trends in age-standardized m...
Molecular Mechanisms and Treatment Strategies of ALK-Positive Lung Cancer: A Beginner's Guide for Patients, Their Families and Carers [0.03%]
ALK阳性肺癌的分子机理及治疗策略：患者、家属和看护人的入门指南
Elena Klenova
Elena Klenova
This review has been written with the intention of explaining to the patients with ALK-positive lung cancer, and to their families, friends, carers and medical teams, in simple terms, the fundamentals, and the current state of knowledge of ...
Myocarditis and Myasthenia Gravis Induced by Camrelizumab in a Patient With Metastatic B2 Thymoma: A Case Report [0.03%]
卡瑞利珠单抗诱导的心肌炎和重症肌无力一例 metastatic B2 thymoma患者接受卡瑞利珠单抗治疗后出现心肌炎和重症肌无力的病例报告
Lingling Zhao,Bo Yang,Yuzhi Li et al.
Lingling Zhao et al.
Thymoma is a rare malignant tumor originating from the thymus epithelium. In recent years, immune checkpoint inhibitors have become an indispensable treatment for cancer. However, the efficacy and adverse events of immunotherapy for thymoma...
Case Reports
Thoracic cancer. 2025 Nov;16(21):e70180. DOI:10.1111/1759-7714.70180 2025
NFAT5 Regulates IL8 to Promote Cell Growth and Migration in Non-Small Cell Lung Cancer [0.03%]
NFAT5通过调节IL8促进非小细胞肺癌的细胞增殖和迁移
Jinliang Chen,Ting Mei,Jingya Wang et al.
Jinliang Chen et al.
Background: In certain types of solid tumors, nuclear factor of activated T cell 5 (NFAT5) plays critical roles in tumor development and progression. However, the subtle regulatory mechanism of NFAT5 in particularly lung ...